FPRX - Earnings call transcript Q3 2020 | Five Prime Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

[00:00:03] Welcome to the Five Prime Therapeutics our Twenty twenty earnings call as a reminder, this topic, cause they're recording it. And I'd like to introduce a host for today's topic, Paul Martin for vice president, investor relations and corporate communications.

You may be.

Martin Forrest

[00:00:21] Thank you, sir. Good afternoon, everyone, and thank you for joining us. the earlier quarter found today company's with results twenty on release website. issued was and press company's twenty third financial the A can be

officer, of Act our today outlook. portion Reform including Litigation David and differ filings. of Securities numerous Private the Today's the those in research, chief development Renkin, today. forward financial under our and factors, Tom regarding will and me from these Andy our Collinge, discussed conference Savic, the SEC and to officer. include the VP Actual Joining chief XXXX, medical call research are statements by Smith, forward executive statements statements may due call respective looking including Q&A our our Dr financial those section programs officer, join Helen chief indicated for looking president results will of of us

expectations change. and could assumptions Our

these disclaim so. the elect in forward to to statements we Tom. our if the Even obligation While any now. call views change over update may Turn looking on specifically to we future, do

Tom Civik

Good treatment afternoon, and benefit Martin. X:XX Twenty for we're joining with at thanks develop conference and our large third Thanks, [XX:XX:XX] quarter us today twenty to working cancer. Prime, options call for with new for everyone, people lasting

five unwavering In program, are to on team's important treatments on our because one the advancing A but today, pipeline. Our I'm cancers the quarterly our timing hard has that Helen with five progress many prime newest biological preclinical hard this responded discovering on potential we David treatment and the that my work, pathways team to will breakthrough updates well This our new the an data the so truly with update introduction and focus optimism is that an proud the challenges novel of for the on making to require remains topline report results five also the financial courage. programs on will trial. that Rincón. brief we to have deliver the an the options. Nandy year clinical on pursue programs. I new update I'm work that proud seven. to say of five on provide one preclinical program provide remarks and for track. and will remain our discuss fight focus

FGF for fight clear had new TFR a have positive. we globally the to FGF modified a chemotherapy combination that whose her targeted tumors Our If line and head potential Unfortunately, results we represented tumors announce tumors gastric their patients to be an evaluating two during cancer with join bema cancer FGF and successful, will first be to FOLFOX negative of overexpressed forward to are research analysis trial important this negative overexpressed thousand with is cancer as with to that will evaluating whose the randomized only Gastric of of cancer negative. Frontline reminder, have end fight a is for the forward therapy. is to worse cancer frontline positive pleased in found of study before the year path Starting whose is us is the for gastric fight that Her cancer. believe two and to gastric leading clear death cause even be that prognosis. global are data with to the top I'm This a therapy positive XX disease. developing we be two And tumors. are Q&A. too hundred the the patients we patients for third that have so trial that path countries Bhima. will retrospective first are the trial reveal report a gastric global be will hopeful first gastric

type of to forward scientific globally. therapies who you trial topline the and by developing before clinical new to inspired allow are challenging for for fight and We look work, collaborate treatment this expertize sharing We the with end that options us patients the desperately year. the results leverage our need of

action, at This fusion class sixty complementary significant on Lakeport program. hot and a and of inhibition, one been dose therapy. We've cells warm that we T milligram two creating program believe as that tumors of have [XX:XX:XX] mechanisms the might checkpoint potential past in a few over of hundred across direct novel, for one for to five created one one enough months. stimulation steps this the The next with at by developed to inform And Moving lines on five year first protein result we end five and the tumor protein. five fifty data and of to prime types patients track. fusion its are enrolling five five remains and expect have monotherapy five was many

program. one Here's with five where today are we five the

safety lung the would five dose with we the For and of in and escalation first now enrolling are quarter, flatboat see at warm enrolling milligrams cohort completed dose in hot small we non tumors now we patients and additional XX are exploratory cohort the expect five in hundred milligram monotherapy, dose patients in We five enrolling escalation Pembrolizumab. and sixty where we cell have one cohort and to a patients cleared and an are with at in hundred activity. cancer second. third clinical the sixty began Early combination five

continue to meaningful on and this will science remains remain We proud unique report this track. We patient I'm lead program, hopeful program with the to that important make that outcomes. to progress

antibody cells antibody the a is seven on to five promising immunosuppressive Now they eliminate the lift is of specifically that to population cells, entire tumor. The t by to restraints seven impose tumor expressed immuno engineered our is these a is five program. preclinical One immunity. a novel oncology This screen. within regulatory one target directed highly and

So this twenty first for week. program submit wind on one a we through two. underway, presenting of poster the announced And next one is twenty studies, development advancing expect and that we yesterday, an Tsitsi seven A&E, five in five be A&E seven is enabling will we to half

for important very now for the the this committed and call our to other me we XX our team us it range my to our XX to to the continue these and five Helen the it over novel programs, accomplishments to to provide progress a I position work to great continue will over details capable hundred preclinical their one thank on time from early one dollars join the in team advance fine expect also significant you twenty before guidance our on detail very hundred turning update of the share Kaskade, gives million with dollar to again the today. We I like year Helen in and to months and print more programs this on company. and six increase to pleasure ago I'll to with and million year. in an one cash allow research to twenty David, Helen? the to in disclose and one I'd pipeline turn And proud with raised investing I'm and work cash program. end about clinical remarks

Helen Collins

[XX:XX:XX] Thank you, Tom.

effort be if or rituximab, antibody evaluation under to gastric an on with Bema, to them cancers. it, update her we as begin monoclonal call be that's two hard Let's positive, negative our and

this As trial from results Tom year. before the end to report the efficacy top of we line mentioned, expect and safety

antibody for It's this This to patients are growth. a be that to advanced which Express's DEMA age. cancer associated five would of in a modified I a is signal S.V. with company trial across checkpoint the cancer. approximately survival negative event the the randomized binding with cells. a stimulating In and be also XX investigators, of Phase this fight, only cancer and contributions effect treating seven gastric acting over TB to take an five hundred FGF, is that negative to pathways partners progression cells XX hasn't that line to and years is standard kinase for will a Front in two FGF in variant nine class and the percent different would first as first and secondly, Fibroblast The in trial frequency the us double FTF. stimulates are I multiple action five thank XX cells, of our clinical well available is program. two of thereby two directly you the XX to Factor, immune be inhibitor. prognosis their antibody months. phase T of benefit mechanism only the survival median target and FGF all overexpression in five cancer of one now before poor of FGF patients, that overexpression, is than for study, cancer walking blocks that the in system the front cancer labs screened free results gastro was you blind the to binding Gastric the protein changed a of If to survival countries fusion XX to our Growth evaluating chemo cancer The by does gastric five, stage are and cancer important families, first directed against months. cells. the simulate were conducting US Asia, And XX class its fitty directly tyrosine bone over be the to with setting a Hard I word whose Pontin Two for genes. the inhibitory Her to to to five to in the to this receptor. turn in FOLFOX the in by line like mutations survival. It and or adding over gastric of and US brought patients similar chemo the be. and approximately only see provides found is approach frontline design novel have positive EGFR BEMA in milestone gastric we destroy to esophageal one ways minute and Europe. inhibitors, year, exciting two end oral the gastric like cancer. are to with

warm the enroll with dose. we past patients at milligram sixty quarter, five continue the hot tumors hundred During monotherapy and to

reside a unique a approach seven programs five wholly regulatory the three in of secret t our within year excited escalation preliminary that to continue depletion those dose to sought and the in expressed the vivo, CCRA antitumor The decisions also five preclinical XXX. five, confirm selective of Turning trial tumors. one a Positive the one on elicits on that by an and cell to [XX:XX:XX] patients that from one combination targets into program. FDA five at of mediator cells owned announce cancer. remains of with track completed enough this that We the program, in-house of strong that to the are have is extracellular expressing to antibody anti eliminate enrollment lung CDX. studies candidates regarding by cohort cellular tumor and offers in announced, screen small pembrolizumab preclinical response. in the mirroring first we expect an Seven One data bioinformatics of make to identify progress steps preferentially end key our we originated our tumult to Tom guide next immunosuppression as of in non cells are one seven we

through Our half clinic twenty the to is of twenty Ayanda plan enabling into two. and first studies move the in

next details week. presenting program about be more presentation will this in a this We poster

been now you and to to data soon. therapy. mentioned patients, I'm to keep We're look will the this The call next cusp shortage potentially we investigators novel As five. for to our actionable track. of have and teams, sharing David. the programs turn an I clinical meaningful and very has five work no of of Tom proud there done earlier, having one, year, forward and And over exceptional these preclinical five on cancer with prime on challenges results

David Smith

our Details in we can results Helen. issued this regarding financial found Thanks, press afternoon. release [XX:XX:XX] the that be

nineteen. facility, fourteen balance two performance XXXX. one in nine to XXst, that as point September decrease This revenues, reduction with strong of five percent with quarterly totaled the Turning thirty lab partially company's was under a capitalism from resulted the license two fifty one for quarter related fight revenue development the the to from was to in administrative to to costs seven for from compensation thirteen or for related twenty twenty clinical third partially as of Phase were and and our to to equivalents expenses or third costs. decrease exceeded offset primarily twenty expenses dollar point from The obligation of a that Phase to decrease related twenty the nine with a general the quarter our decision due to facility seventy nine depreciation increase was a four was by percent, third collaboration one BMS third an The miscellaneous point quarter million of primarily our or cents design costs related a seven BEMA and to pursuant point one per six marketable offset essentially by at nineteen. million charges of revenue sublease five due These to five twenty expense impairment million point nine the administrative third hundred lower five was twenty Cash, two three and quarter companion share operating programs. trial in in third securities as thirteen amend five impairment cash the as million manufacturing for and the a increase lower nineteen. by October point revenue December to and quarterly per finished attributed of expenses allocated of the bio cents twenty research November subleases. allocated three point and general collaboration diluted quarter twenty of with twenty A twenty by twenty percent nine six of twelve preclinical decrease an point for restructuring, from diluted primarily and quarter four our one of decrease quarter from loss portion analytics, XX for third the four million the twenty the diagnostic cash of million Twenty increased million due million twenty million twenty decrease decrease offset The loss was share, twenty central thirty of to other million lab twenty to to or million charges quarter compensation, and that two point resulting Net net the well costs point were twenty reductions lower and the point to third and compared of four our costs six the position, basic portion we costs collaboration Twenty a by for of quarter twenty, costs compared and basic million for for lower trial million nineteen. point costs, hundred and the one and nineteen along sheet.

twenty estimate like a This used year to use Looking cash operator in continued be of for refund net the five Twenty ahead, call ending The twenty our five turn hundred Carers cash our securities increase an in I the to Twenty in seventy and our discipline, investing increase portion Twenty to represents million, equivalents and extend of back Q&A our the and full and financial call. tax one marketable cash two. continue we us cash runway our twenty over between Act and position operating now under hundred and cash, with that pipeline will XX the in into allow the million. one the an ATM. our reflects end between to guidance expect year activities cash

Operator

need please the the press we Please while telephone key. to by the [XX:XX:XX] withdraw to on Q&A question, stand question, press one you pound compile ask your your Thank losses. the you to

of Our comes first the from question with the line rally Guggenheim Securities.

is open. line now Your

Unidentified Analyst

versus I if a Great, how some to performed follow the control data just relative there's maybe of thing. control, can drugs the far taking That's the know timing we question, of infer of have data for historical of the [XX:XX:XX] arm the events, And outcome one up. or this from generally? thanks wanted the anything as on as to sort pace

Tom Civik

little program. [XX:XX:XX] comment, sort population of this Sir, we've the in of can just just Helen's fifty and or survival of population. months. plug shared we've between a on last quarters. free for five November a what in Why it's patients average, and walk get time patient last so averages Helen the the year program survival I and I The what over patient then started in fill than you for to the as couple heard is, think, is some gaps, one same year don't here. for can fifty hundred We the very not somewhere exactly six about good. back and with bit back seven It overall in And less progression hundred

some the probably retrospective than less to a year patients whose be. fact some And out FGF for analysis to overexpressed all tumors point that it's

is we is So the we available trial on right that all now blinded. that that completely data the

been on yet Helen, we to So analysis add that. like trial. know if to on don't any complete don't of the site there's anything have that's else information the I any you'd

Helen Collins

right guiding us that, you I saying of know, to year, you of into think, this sort next the think we've we're [XX:XX:XX] been year, and No, no, of I mean, that. beginning heard I end as the of say, middle falling

the as data think sure way. along I predicted. along great team And did So just the making over and gone job the again, a we things have this came

going that's to exciting. so be And

Unidentified Analyst

different tumor guess up, you one here sort And for see five five patients, program. of if types number know that. may sense the of that for next just five one we update Thanks. Thanks Great. the on five, any for us the the [XX:XX:XX] of give sort follow quick can with one of I the

Tom Civik

[XX:XX:XX] Sure.

enrolling tumors at long with and announced, been would neck. patients milligram hot expect, and head, the dose. you monotherapy are we as melanoma, we've hot warm the we of So tumors those XXX And that tumors type warm

And at just should right so the exclusively seeing lung That combination trial. And five is we're dose pembrolizumab, announced one we're the selecting of and now also first plus that cancer then we clinical efficacy. patients. think patients completed we be dose that those we five our we cohort that's

the have end program. the we we should before patients we inform that on next expect in-house the in year hand steps So of the enough to

Unidentified Analyst

the [XX:XX:XX] Great. you update. Thank for

welcome. You're

Operator

you. Thank [XX:XX:XX]

Our next learned, question comes from not open. we Jonathan SVB as with Leerink, Chiang

Jonathan Chiang

for thanks taking questions. guys, my Hi, [XX:XX:XX]

a five should be the used? we is relative positioning and level, how voice at question about high landscape thinking First treatment of where one five to your

Tom Civik

Helen [XX:XX:XX] you to want want do you on get to this started one?

Helen Collins

doesn't mean, that [XX:XX:XX] I of right, obviously, I your require comparison make think mechanisms the people I action of you're cell, people stimulates that I inhibit so to the also say T is sometimes this to boy. the Right. be activated. for because mean, and one it to cells think directly Yeah, T drug

cells. So well, it's on know, as as, to already naïf work going you activated T

et will And we non So except these really of we talked warm patients think be of T cell this cetera, about, one melanoma, any to melanoma, makes that's all range you that renal that's end been and or you yesterday Essentially, patient head any should voice. we going the response data not alone. cell know, expect have that think, from would your know, tumor. we'll it your you that the to have year sunny, better boy you by for there, small seeing to And have bladder neck, would as that the the PD or hot I And expect a saying think for work. this into prior. of population, would be cells the by terms the tumor what in got than be rationale idea

think allow to do we going seeing him see a something I signal that to So helped that's or us of are different? we different That what's least down. have at potentially

Tom Civik

broad this why just we'll we're [XX:XX:XX] and that program, I maybe different have to so think is many applicability that that, excited for tumors potential I add the as really about end think lines different interrogate the I announced be multiple data steps think that the that's does it year, against to clear. continue will to before of next program the have the therapy.And we of will

Jonathan Chiang

investors one end? question to data second more [XX:XX:XX] should the from expect Thank Got it. and can data guidance on investors also year to you expect granular when by clinical five, program? five on see see where you, provide Should

Tom Civik

[XX:XX:XX] been is this we've what program. on in to we intentional reiterate and Yeah, the the one end year to on inform have of very information saying enough I will next steps communication topic before to think just five our the it, five and been in-house the we've that

to we'll have enough of But step. how yet next We information. where, we have what, that the and decision not believe we'll made inform share in-house on end a before do the when patients year

Jonathan Chiang

levels. [XX:XX:XX] last is indicated Got remind me five you've that it. you. at are for one view? question believe you reasons Thank you me, dosing And one five Can active that before the just for therapeutically what

Tom Civik

take want When down. you [XX:XX:XX] to

Helen Collins

the [XX:XX:XX] where, we know, into expected would and T pharmacokinetics, the when then to on that Yeah, that a using dose based have proliferation our the occurences, we modeling. so we see the of clinic on you the where dose increase cells correlation predicted went it's in started based dependent at receptor preclinical between no data

no, that's we that saying, range dose OK, efficacy had. that's the think this there been so evidence a is we've that be this the now to And be in where should

it. We will see

modeling and would from So the the a it's the combination of I precolonial say the based clinical. some pharmacodynamics on pharmacokinetics to of

Jonathan Chiang

Got you very you. Thank [XX:XX:XX] it. Thank much.

Operator

[XX:XX:XX] Thank you.

comes Our line next line talent, your the right? is with open, force now from question of

Unidentified Analyst

in [XX:XX:XX] just is current question if just on I'm the environment. could curious the trial. you the completeness first comment data in My

follow how and delayed if due may up patients Specifically, have many or you covid. have to skipped scans data on

Tom Civik

and globe. I'll Helen did was I this want our going all reiterate this then that [XX:XX:XX] me let start that mentioned her are across team let the maybe with comments, the in this challenges with that extraordinary Yeah, to one on just but and work Helen

the and mentioned, of different all a is, by trial covid XX know, in different in countries this impacted them being we were way. As fight you

QX over pivot was could cards. we and if So to up don't could we've specificity we about measurable so much the we off we the could information about once reason a on to QX I we was of really wanted such that to going guiding range data that sure were and to clean to be ensure make that tighten we we the And confidence the know can there's of turn that. the we've question impact we you with learned that once share covid the the of anything

Helen Collins

[XX:XX:XX] in No, back people we've who before of I couldn't scan get when elsewhere think get able but worse to we that their particular to it's I at clinic mean, a I were but mentioned maybe scanned. how get handle go back course, weren't much have think, the did to then, some as spring patients into now, to least it, sure

most So stopped know, been was not small November. not third And, is their is and much It gastric the you patients. This also one world of has line, number for impacted and again, the medical that a US cancer. in very and trial. global enrolling as patients. We of is maybe cancer first said care we last the as

are get and their got get to in So their treated, still they patients treatment that scans. getting

quickly makes shouldn't the data of very affect any did the have is. data. in the about And so how nothing zero, think ability little way I that certainly impact. We and we'll feel very say we not much confident us but

Unidentified Analyst

in includes kind see it bar Phase you and for trial into this ultimately? trial, just of for second [XX:XX:XX] question think a do three ratio then setting you're is curious the that need study my what to terms the hazard monitoring going of justify in to we And first

Helen Collins

exactly I'm [XX:XX:XX] Now, sorry, yes. we did

this usually the what and and they So, point all the so, Ok, of line us status we're telling but you you think, the And impatient gastric when see being go wait you'll for know, challenges front you mean, things me in But cancer. impatient I fail, hell I'm range. you to have someone I'm the country person of to the that know, Tom. quo. hazard across past the for, the and know, in many supposed failed the know, the looking I an is you is eight ratio I'm

the few closer seven. know, successful been You to that's had point been

So, will But area you that's looking at. West. that response be the looking that's in we the we're rate that know Right. at

will to so, And drug we board know, what no all doing benefits we think, is although if see this three primary. endpoints, the you that across we our would expect

maybe and that think are important in the to first note it's to this anyone that FGF And patients just prognosis these line front significant is is that, patients I just is So gastric to maybe overexpressed that study quite really add a cancer the population a the need. to on bad. so think I time be patient with for

drug targeted new being without a positive. last five trials So feel in drug approved, the XX years, we like it's the

Tom Civik

advance we forward some important as the program. really path have conversations for a to There's [XX:XX:XX] us

Unidentified Analyst

my thanks taking questions. much you. for very Great, Thank [XX:XX:XX]

Operator

[XX:XX:XX] Thank you.

Butler good I Ralph with question asked morning. next ILADS, Our Capital Tony

Tony Butler

That's would we update same? when stayed of case cohort also up. two, I if case the has Thanks Enron? may. And you have five include view one the much, of [XX:XX:XX] five. kind with Could And Good one afternoon. maybe the monotherapy, of you roughly this and or the later one, increased characterize because on the provide very that combination posed first your question, follow the that I number dose and point Helen. then On it's year

Helen Collins

not be that saying first, [XX:XX:XX] something not clear may be the I we five because will end five Well, well, necessarily publicly try answer as your the we have just year we to one data. want I'll at reiterate we of to second the about

next will say we what can our is saying we're internally have what data So that enough believe that we are. we steps

that Australia in the be terms you quite So of in been I so conducted mean, may South is and there'll recall, Korea. announcement being trial, enrollment. I some steady. can't as We've promise really public

then in care they've they've know, patients well. manage relatively taking done general, you been to and able So, cancer of managing covid and

by month, So nobody anxious a Suddenly roll now. at when we're there'll Comverse. or month we And we will where week our but mean, be average look track. something. I on maybe get but

Tony Butler

may last The these and is preclinical not as the if I for going but about others, sure to just curious those anything to utility you on And and program could that you. licensed I'm mean, seven you combination have are In but with if Thank other agents, then your then obviously chance do the certainly you. on have any Thank on there Chiliad. campus, the other so data some what's refractory know, with say was on curious recently necessarily intelligence programs. you one [XX:XX:XX] versus demonstrated that I'm some extent patients. marketplace, CCRA, I'm some question others one have, the unique in from that that have there's you

Tom Civik

and for all done expertize to And Why we program It's [XX:XX:XX] quite we've target. Rankin, of to really bring to don't be you excited We're announcing I'd a just this some technical team had some we a exceptional our forward this leverage And seven get who targeting time. here works that tricky with to Andy the program. work. heads it's been working hour I five team. on one started to up Andy been research introduce our CCRA. love We've

to able go. it, excited behind quickly forward also what steps we next And so as to the very but science and move excited the were it we're quite of our complexity about build

So, Andy, fill here. maybe maybe in can gaps you some

Andy Rankin

definitely. Thanks, [XX:XX:XX] Tony. Yeah, Tom. Yeah,

targets. think ours. stage are there. excitement volumes in interest early similar that We're that There are there other programs that this the CCRA, out around like are Now, aware speaks and out other to targeting there are programs the I there

a to is moving available presenting be We're And so What we and presentation kind the we're the really ahead. you is I about And to well. information that after full know, program about have at additional know, say limited week. that, we're of the you looking And, can poster there right steam excited fairly that's XX poster there. information will program that be going forward more sharing we're next now. as

Tony Butler

much. very Thanks [XX:XX:XX]

Operator

Thank [XX:XX:XX] you.

line of question Our from Jim next with comes security. Birchenough the

Your line is open. now

Unidentified Analyst

this come, afternoon. [XX:XX:XX] Good Jim, afternoon. may It

there over been you the is First for we've significant know BEMA in is been question can you've let on clinically quarter. last data maybe statistically doing background the and a as us then mature increase to Bema, waiting what this. the in And mature

in in detail So and steps of of on expect VEMA? what should plans next timing future we terms

Tom Civik

Helen, [XX:XX:XX] up one. take the with then and I'll don't the why one first second you follow

Helen Collins

you double know, placebo know, being patient study [XX:XX:XX] Well, controlled, we population. I this I about the nice you thing mean, that is designed blind, think selected how

As trial our know, to read we've actually Ventana done down. to with should we've seediest quickly we and move the work that all out have this PGD and you is ready have be go got top able to will very really design positively,

that think your of question. kind answer I So

Unidentified Analyst

product shelf made and you've and one go nuts [XX:XX:XX] in I you likelihood, of ahead move extend to ticking be all of clinic. I the as ready would a you need to of that, as manufactured the mean, just of you bolts of one And partner life the a boxes partner. with sort the all the points into know, this product attractive the is, be you to to possible make is think know, that to

Tom Civik

reinforce yeah, prepared program multiple I times, once well to could to be and I say we've well. investigators [XX:XX:XX] quickly really the sites we we'll Yes, of it the about think, the quickly. last until as and was pivot we year executed of the in mean, see started me as we the and a world ready trial. that November advance very across and to mention data designed Helen you've And up the feel confident the I design. were trial I'll heard the learned three Phase fight lot Obviously,

next information think as that program. be quickly And leveraging about steps so the we we would for

globally You to we we explore are line, will multiple know, in we gastric us mention outside options after are When commercialization options we're when once overexpressed we see different the of cancer. clearly partner we positive, that two. I many and the And that about heard patients of think have this to we United a a if term States. be see us them program data. fully fortunate front be And in need in to the results there's lot to product, of it's that get of TFR XXXXXX the prepared the you've the times there, phase for short will front enough

Unidentified Analyst

it's Ok, on then not one to And certainly side [XX:XX:XX] me. thanks. and lost side, moving

one and five patients payment fifty and also cases, and two called have that's You hundred program one you hundred know. fifty

of puzzled getting you one little to And expect with So, five I higher you over remind autoimmune by with orders doses. we see us a I'm cross events can think know, magnitude and a yet should mechanistic why Yervoy not excessive five?

Helen Collins

[XX:XX:XX] pharmacokinetic. So one the mechanistic now terms believe so with to the so it in do we we that has of some of of have answer to to that sort

And or be an has in troughed molecules, be the to or has activation, requiring a than peak level shorter whereas your life one of this certain half schematics general, And kept. inhibitory organism a going level. Yervoy. is more thinks to it's So the for

of And get milligrams, sure is to some makes you get kid with in this the be the three given and potential hit There think are you really to just eight you so know, four is three is that that higher every this question, advantage looking can second say how, our whole six the but dose, weeks, your we this I'm high certainly the about a EPS And twenty then how the which to how you Dosso drugs, drug have use trough that preclinical. peak you and there that stimulate hundred make is question the avoiding five essentials? you maybe the weeks. second around constant eight, then somewhere may throughout

Tom Civik

I so [XX:XX:XX] know, you I think, mean, yeah.

Helen Collins

toxicity. when extent. stimulating titillates mean, Right. would any expect inhibiting I think T to you're twenty some get it to some, get you time we know, stimulating expect or doing you're to would by So cells, still [XX:XX:XX] to eight I

window The of going of however of superior sort will, therapeutic XX. the I the stimulation. you so this, intermittent So to because think received TSA is whether if question be

you kicking little I the is know, think like, the see, you before bit heard a analogy right. ball,

you So if that that rolling a the and that you give quick therapeutic it is additional of the that's we window. using kick and have enlarging by mechanism, think you then then ball how organism

Tom Civik

the how And for then milligrams. many three say it's XXX can three. And you Thanks those patients were right you many combo, the to [XX:XX:XX] now, to by how a dose XX standard of lot. intend and milligrams

Unidentified Analyst

welcome. [XX:XX:XX] you. You're [XX:XX:XX] Thank

of line J.P. Our the comes Eric Morgan. next with Schlosser from question

now Your line open. is

Eric Joseph

[XX:XX:XX] Thanks for the taking questions.

Well, trend with think further about for or big one advancing what Does fight. on program of seeing on warrant do larger clarification advancing have you follow And one update would you study? bit OS? the talk a in I And on couple. type Can then be compelling up with. a PFS not? a enough to the a one the either program Just benefit it's a hinge on

Tom Civik

for the question. [XX:XX:XX] Yeah, thanks

able the think made a obviously We two all sooner well main that able gets back the us it's You know, behind see very and still exist one trial would that we very different note, us benefit the steps. trial do bridge was this patient to look the being that rate. we're think subgroups under that of next Phase is big That's is here before. might primary it be two hopeful I than population. right a sorts are as this there. to that OS able end converting before inform to changes at benefits to you of large this response the will converting this to converting really of Important though, to, we'll for we the have But really still phase to pass water as know, again, of endpoint data will and And, they we're results the clear to much the driver the be to interrogate determine But to next this of tracking I step. point. we'll year all allow

inform And so that will that we where go.

Eric Joseph

on earlier of of as exploratory activity, GI perhaps further tolerability fifty that with events sort to need on any XX, terms anticipated in what predicted the beyond to was up XX, of anything how And five, follow And question do headroom you there way see [XX:XX:XX] correspond tolerability, about your dose, XXX we order adverse about symptoms was boy? one profile in biologic or then based to of an be? just selected if an in to dose know safety escalate the

Tom Civik

down? [XX:XX:XX] long want to take How you do

Helen Collins

that and going just of the on we that's. have trying higher to as has in er I [XX:XX:XX] And mean, in what markers we Yeah, And the said trying patients. certainly adverse say before, five you the with events. may mean, just dose more I seen to cells with not circulating seen we've still to doses. before. to commented to consider I'm do we've We said the that t XX

Eric Joseph

OK, great OK, is enough. great. This fair Right. [XX:XX:XX] a question.

Tom Civik

[XX:XX:XX] Thank you.

Operator

to this further would closing at civics are no now questions turn you. comments. the like back There to clock time. Thank for [XX:XX:XX] I

Tom Civik

the antibody preclinical very one preclinical introduce year. novel of newest by seven, months. We at our and of end meaningful and reflects data raised outcomes program five million for tumors trial monotherapy five for the soon. we've one hopeful program to Today, urine joining warm their on last our inform two. I'm directed firefighting discipline enough pipeline, and preclinical by advance the the range. and cash programs done on today And to with extends enrolling patients novel in few we all very patient have the program continued to heart to will end us sixty at we future. data we on for five the unwavering [XX:XX:XX] And team hundred and and This carskadon the that next one and dollars provide translates our work twenty, this the This Thanks over a the of expect financial five focus and on All Secret. right, well, is you. twenty to year's the been on thank year. we've that one steps questions track dose The our another hundred track, finally, hundred and runway proud report five I'm we science our our our near remains thanking first to milligram for focus before close details that expect I'll today. into despite we're into the clinical topline challenges. from this

So safe. say care. hope with that, I joining today just Take thanks I and us all for to want stay you

Operator

now concludes disconnect. Thank your conference participation, may for you gentlemen, and Ladies you [XX:XX:XX] this call. today's

Martin Forrest	Vice President, Investor Relations & Corporate Communications
Tom Civik	President and Chief Executive Officer
Helen Collins	Executive Vice President & Chief Medical Officer
David Smith	Executive Vice President & Chief Financial Officer
Andy Rankin	Vice President Research
Jonathan Chiang	SVB Leerink
Tony Butler	ROTH Capital
Eric Joseph	J.P. Morgan
Disclaimer: NEW We are providing this transcript version in a raw	machine-assisted format and it is unaudited. Please reference the audio for any questions on the content. A standard transcript will be available later on the site per our normal procedure. Please enjoy this timely version in the interim.

Five Prime Therapeutics (FPRX) 3 Nov 202020 Q3 Earnings call transcript